A26-Week Open-Label Study of Quetiapine in Children with Conduct Disorder
The aim of this study was to describe the long-term safety and effectiveness of quetiapine in conduct disorder (CD).
This was an 18-week outpatient follow-up study of an acute trial that enrolled aggressive children ages 6-12 years with a primary diagnosis of CD. To be enrolled into this study, subjects had to have successfully completed participation in the initial 8-week, open-label, outpatient quetiapine trial. Psychometric measures included the Rating of Aggression Against People and/or Property Scale (RAAPP), the Nisonger Child Behavior Rating Form (NCBRF), the Conners' Parent Rating Scale (CPRS-48), the Clinical Global Impressions Scale of Severity (CGI-S), and the Children's Global Assessment Scale.
Nine males with a mean age of 8.9 (SD = 1.2) years were treated. The median quetiapine dose at end of study was 150 mg/day (range 75-350). Mean psychometric scores did not change substantively from baseline. No patients experienced extrapyramidal side effects. Three subjects discontinued due to study nonadherence. No patients discontinued treatment due to an adverse event.
These preliminary data suggest that quetiapine might be a generally safe and effective maintenance treatment for aggressive children with CD who initially respond to an acute therapeutic trial of quetiapine. More research is needed to confirm or refute these initial findings.
Available from: umd.edu
[Show abstract] [Hide abstract]
ABSTRACT: Modelling error can be the cause of bad performance when optimal feed-rate profiles computed for a particular model are applied to the actual plant. This paper suggests the modification of the input trajectory from batch to batch, by using information from previous batches to modify the trajectories that are applied to the subsequent ones. The proposed approach does not required the remodeling of the process, but instead it redermines the input profile directly, so that a steady improvement is accomplished from batch to batch.
American Control Conference, 1989; 07/1989
Pediatric Annals 10/2007; 36(9):564-74. DOI:10.3928/0090-4481-20070901-08 · 0.61 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Disruptive behavior disorders, including conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified, are serious conditions in children and adolescents that include a behavior pattern of violating the basic rights of others and age-appropriate rules or standards and may include aggressive behavior. Although no pharmacotherapy is currently approved for use in this population, evidence suggests that atypical antipsychotic treatment may be useful in patients with these conditions who present with problematic aggression. Currently, research on risperidone shows it to be effective in treating aggressive behavior in this patient population. Limited research is also available on olanzapine, quetiapine, and aripiprazole, but more research is needed on these and other agents. As with any pharmacotherapy, adverse events (including weight gain, headache, and somnolence) should be carefully considered with these medications, especially in children and adolescents, and it is important to properly dose and monitor patients during medication therapy.
The Journal of Clinical Psychiatry 02/2008; 69 Suppl 4:9-14. · 5.50 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.